Login to Your Account

Financings NEWS

Apellis Pharmaceuticals Inc. extended its string of financings with a $60 million series E preferred stock round led by Sectoral Asset Management that included new investors Sofinnova, Vivo Capital, F-Prime Capital Partners, investment funds advised by Clough Capital Partners LP and Venbio Select.

DUBLIN – A certain DNA endonuclease from Streptococcus pyogenes, Cas9, has gained enormous prominence as part of the revolutionary CRISPR-Cas9 genome editing system, but Hansa Medical AB is making waves with a different enzyme from the same bug.

Homology Medicines Inc. CEO Arthur Tzianabos told BioWorld that the new $83.5 million in series B money should let the firm "move our lead program all the way through a phase I/II proof-of-concept trial" while edging toward the clinic.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: